晚期糖基化终产物（AGE）在人体内的半衰期较长，正在成为有效的诊断指标。专注于 AGE 交联破坏剂的早期干预研究在心力衰竭患者中显示出令人鼓舞的结果，为疾病进展监测和治疗效果评估铺平了道路。 AGE 是糖与蛋白质、脂质和核酸相互作用的非酶反应的副产物。这些化合物具有改变许多生物过程的能力，从破坏分子构象和促进交联到改变酶活性、减少清除和损害受体识别。 AGEs 通过刺激细胞内信号通路造成的损害与各个器官系统慢性疾病的发作有关。本综述综合了 AGE 的特征以及它们在不同生理和病理状态下表达所带来的挑战。此外，它还强调了 AGE 的临床相关性以及旨在减少 AGE 积累的最新研究突破。版权所有 © 2024。由 Elsevier Inc. 出版。

Advanced Glycation End-products (AGEs), with their prolonged half-life in the human body, are emerging as potent diagnostic indicators. Early intervention studies, focusing on AGE cross-link breakers, have shown encouraging results in heart failure patients, paving the way for disease progression monitoring and therapy effectiveness evaluation. AGEs are the byproducts of a non-enzymatic reaction where sugars interact with proteins, lipids, and nucleic acids. These compounds possess the power to alter numerous biological processes, ranging from disrupting molecular conformation and promoting cross-linking to modifying enzyme activity, reducing clearance, and impairing receptor recognition. The damage inflicted by AGEs through the stimulation of intracellular signaling pathways is associated with the onset of chronic diseases across various organ systems. This review consolidates the characteristics of AGEs and the challenges posed by their expression in diverse physiological and pathological states. Furthermore, it highlights the clinical relevance of AGEs and the latest research breakthroughs aimed at reducing AGE accumulation.Copyright © 2024. Published by Elsevier Inc.